抗レトロウイルス療法を受けているHIV陽性患者における組換えインターロイキン-2の評価に関する国際研究

基本情報

NCT ID

NCT00004978

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

4,150

治験依頼者名

National Institute of Allergy and Infectious Diseases (NIAID)

概要

The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy. Patients will be followed over a minimum of 4 years to study the long-term effects of rIL-2 on their HIV disease progression. Anti-HIV therapy has been very successful in treating HIV positive patients and in keeping viral load (level of HIV in the blood) low. However, anti-HIV drugs cannot completely rid the body of the virus, and the immune system is never completely restored in HIV positive patients. Doctors hope that giving patients recombinant interleukin-2 (rIL-2) in addition to their anti-HIV therapy will help improve their immune systems and keep them healthier over a longer period of time. rIL-2 is a hormone naturally produced by the body during an immune response to a microbial infection.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)